Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

BBV152 – Bharat Biotech vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6289 participants
High

BBV152 – Bharat Biotech vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16973 participants
High

BBV152 – Bharat Biotech vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16976 participants
High

BBV152 – Bharat Biotech vs placebo

All‐cause mortalitye

BBV152 – Bharat Biotech showed no clear difference in all‐cause mortalitye compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.17, 1.46]
1 study · 25753 participants
Low

BBV152 – Bharat Biotech vs placebo

Systemic reactogenicity events

BBV152 – Bharat Biotech leads to higher systemic reactogenicity eventsg compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.34 [1.15, 1.58]
2 studies · 25925 participants
High

BBV152 – Bharat Biotech vs placebo

Any adverse eventi

BBV152 – Bharat Biotech showed no clear difference in any adverse eventi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1 [0.94, 1.07]
1 study · 25753 participants
High

BBV152 – Bharat Biotech vs placebo

Serious adverse eventsi

BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.65 [0.43, 0.97]
1 study · 25928 participants
High

BBV152 – Bharat Biotech vs placebo

Local reactogenicity events

BBV152 – Bharat Biotech showed no clear difference in local reactogenicity eventsg compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.08 [0.95, 1.24]
2 studies · 25750 participants
High

NVX‐CoV2373 – Novavax vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NVX‐CoV2373 – Novavax vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 42175 participants
Moderate

mRNA‐1273 – ModernaTX vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 31632 participants
Moderate

NVX‐CoV2373 – Novavax vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25452 participants
Moderate

NVX‐CoV2373 – Novavax vs placebo

All‐cause mortalityh

NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.9 [0.3, 2.68]
1 study · 29582 participants
Low

NVX‐CoV2373 – Novavax vs placebo

Systemic reactogenicity events

NVX‐CoV2373 – Novavax leads to higher systemic reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.21 [1.17, 1.25]
3 studies · 31063 participants
High

NVX‐CoV2373 – Novavax vs placebo

Any adverse eventm

NVX‐CoV2373 – Novavax probably leads to higher any adverse eventm compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.15 [1.05, 1.26]
5 studies · 46231 participants
Moderate

NVX‐CoV2373 – Novavax vs placebo

Serious adverse eventsm

NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.74, 1.14]
4 studies · 38802 participants
Low

NVX‐CoV2373 – Novavax vs placebo

Local reactogenicity events

NVX‐CoV2373 – Novavax leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 2.78 [1.99, 3.88]
3 studies · 31063 participants
High

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28674 participants
Moderate

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found